Lung Cancer Immunotherapy with Dr. Leena Gandhi

Dr. Leena Gandhi leads a discussion on the latest immunotherapy for lung cancer patients. #CRIsummit #immunotherapy #LungCancer https://www.cancerresearch.org/virtua... In this video, Dr. Gandhi addresses: Different forms of lung cancer and different stages of disease PD-1 or PD-L1 checkpoint inhibitors Cancer immunotherapy clinical trials Combination therapies, such as surgery + immunotherapy or radiation + immunotherapy Cancer biomarkers, such as PD-L1 or TMB-H Treatment regimen decisions, such as length of treatment Partial vs complete response to treatment Cancer immunotherapy side effects Flu vaccine and cancer immunotherapy Lung cancer care during COVID-19 Advice for those newly diagnosed with lung cancer As the most common cancer worldwide, lung cancer impacts approximately 2.1 million people each year. Hope for millions is on the horizon as the lung cancer death rate in the United States has dropped dramatically over the last few years with the introduction of new treatments, including immunotherapy. Immunotherapy for lung cancer, alone or in combination with conventional treatments, can significantly improve outcomes for lung cancer patients. https://www.cancerresearch.org/immuno... Dr. Leena Gandhi is the director of the Center for Cancer Therapeutic Innovation at Dana-Farber Cancer Institute. She was previously the director of Thoracic Medical Oncology at NYU and the head of Immuno-Oncology Development at Eli Lilly. She was a lead investigator on a pivotal phase 1 clinical trial that showed the usefulness of using PD-L1 as a biomarker for patients receiving anti-PD-L1 checkpoint immunotherapy as well as the lead investigator of a pivotal phase 3 study showing the survival benefit of adding pembrolizumab (Keytruda®) to chemotherapy in the initial treatment of metastatic lung cancer. She continues to work on evaluations of potential biomarkers that can better extend and refine the use of immunotherapies and combination therapies to maximize benefit for the most patients. The 2020 CRI Virtual Immunotherapy Patient Summit is part of the Cancer Research Institute's Answer to Cancer Patient Education Program. Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. https://www.cancerresearch.org Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.